NabholtzJ.M., SennH.J., BezwodaW.R.: Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy.J. Clin. Oncol.17: 1413, 1999.
2.
ChanS., FriedrichsK., NoelD.: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.J. Clin. Oncol., 17: 2341, 1999.
3.
NabholtzJ.M., FalksonG., CamposD.: A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first line chemotherapy for MBC.Proc. Am. Soc. Clin. Oncol.18: A485, 1999.
4.
EspositoM., VenturiniM.O., VannozziG.: Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients.J. Clin. Oncol.17: 1132, 1999.
5.
NabholtzJ.M., MackeyJ.R., SmylieM.: Phase II study of taxotere (docetaxel), doxorubicin (Dx) and cyclophosphamide (CTX) (TAC) in the treatment of metastatic breast cancer (MBC) (Meeting abstract).Proc. Am. Soc. Clin. Oncol.16: A518, 1997.
6.
SawadaN., IshikawaT., FukaseY.: Induction of thymidine phosphorilase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts.Clin. Cancer Res.4: 1013–1019, 1998.
7.
ASCO Special Article: Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer.J. Clin. Oncol., 15: 2996–3018, 1997.
8.
FossellaF.V., LeeJ.S., KauS.V.: Docetaxel (D) for platinum-refractory non-small cell lung cancer (NSCLC): comparison of phase II results to historical controls (HC) (Meeting abstract).Proc. Am. Soc. Clin. Oncol., 16: A1682, 1997.
9.
BurrisHA3rd: Single-agent docetaxel (Taxotere) in randomized phase III trials. Semin.Oncol., 26(3 suppl. 9): 1–6, 1999.
10.
GandaraD.R., VokesE., GreenM.: Docetaxel (Taxotere) in platinum-treated non-small cell lung cancer (NSCLC): confirmation of prolonged survival in a multicenter trial (Meeting abstract).Proc. Am. Soc. Clin. Oncol., 16: A1632, 1997.
11.
FossellaF.V., DeVoreR., KerrR.: Phase III trial of docetaxel 100 mg/mq or 75 mg/mq vs vinorelbine/ifosfamide for non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy (PBC).Proc. Am. Soc. Clin. Oncol., 18: A1776, 1999.
12.
ShepherdF., RamlauK., MattsonL.: Randomized study of Taxotere (TAX) versus best supportive care (BSC) in non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy.Proc. Am. Soc. Clin. Oncol., 18: A1784, 1999.
13.
CunninghamD., PyrrhönenS., JamesR.D.: Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.Lancet, 352: 1413–1418, 1998.
14.
RougierP., Van CutsemE., BajettaE.: Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metatstatic colorectal cancer.Lancet, 352: 1407–1412, 1998.
15.
DouillardJ.Y., CunninghamD., RothA.D.: A randomized phase III trial comparing irinotecan (IRI) + 5-FU/folinic acid (FA) to the same schedule of 5-FU/FA in patients with metastatic colorectal cancer as front line chemotherapy.Proc. ASCO, 18: 233a (abstr. 899), 1999.
16.
SaltzL.B., LockerP.K., PirottaN.: Weekly irinotecan (CPT-11), leucovorin (LV), and fluorouracil (FU) is superior to daily × 5 LV/FU in patients with previously untreated metastatic colorectal cancer.Proc. ASCO, 18: 233a (abstr. 898), 1999.
17.
FinlayC.A., HindsP.W., LevineA.J.: The p53 protooncogene can act as a suppressor of transformation.Cell, 57: 1083–1093, 1989.
SlichenmeyerW.J., NelsonW.J., SlebosR.J.: Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage.Cancer Res., 53: 4164–4168, 1993.
20.
BishopJ.M.: Cancer: the rise of the genetic paradigm.Genes. Dev., 9: 1309–1315, 1995.
21.
KastanM.B.: The p53 tumor suppressor gene: a multifaceted cancer threat.Adv. Oncol., 12: 3–7, 1996.
22.
TimmonsT., BurtK., ChemaB.: Biodistribution of AdP53 (INGN 201) in a phase I/II trial of gene therapy for non-small cell lung cancer (NSCLC).Proc. Am. Soc. Clin. Oncol., 17; A1660, 1998.
23.
GoodwinW.J., EsserD., ClaymanG.L.: Randomized phase II study of intratumoral injection of two dosing schedules using a replication-deficient adenovirus carrying the p53 gene (Ad5CMV-p53) in patients with recurrent/refractory head and neck cancer.Proc. Am. Soc. Clin. Oncol., 18; A1717, 1999.
24.
NemunaitisJ., Bier-LaningC.M., Costenla-FigueirasM.: Three phase II trials of intratumoral injection with a replication-deficient adenovirus carrying the p53 gene (Ad5CMV-p53) in patients with recurrent/refractory head and neck cancer.Proc. Am. Soc. Clin. Oncol., 18; A1661, 1999.
25.
Bier-LaningC.M., VanEchoD., YverA.: A phase II multicenter study of Ad5CMV-p53 administered intratumorally to patients with recurrent head and neck cancer.Proc. Am. Soc. Clin. Oncol., 18; A1712, 1999.
26.
Costenla-FigueirasM., BetticherD.C., Del CampoJ.M.: A phase II trial of Ad5CMV-p53 as a single agent in recurrent/refractory head and neck cancer examining vector biodistribution and horizontal transmission under normal life conditions.Proc. Am. Soc. Clin. Oncol., 18; A1714, 1999.
